SYGNIS signs distribution agreement with Chinese Nanodigmbio Co. Ltd.
- Distribution agreement for China, the biggest market in Asia and one of the fastest growing life science markets in the world today
- Nanodigmbio is a leading Chinese life science distributor with focus on molecular biology, protein research, cell biology and diagnostics
- Distribution agreement covers the entire SYGNIS portfolio of powerful tools addressing key challenges in next generation sequencing (NGS) and single cell analysis (SCA)
Madrid, Spain and Heidelberg, Germany, August 20th, 2015 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced that it has signed a distribution agreement with Nanodigmbio Co. Ltd. for the commercialization of SYGNIS’ proprietary product portfolio in China. China is set to become a crucial player in the healthcare and life sciences industry and is expected to become the global leader in drug discovery and innovation within a decade. According to the Ministry of Health, the Chinese government took various initiatives to promote genomics research, and plans to invest more than $300 billion in biotechnology in a five-year program ending in 2017.
With this agreement, SYGNIS grants Nanodigmbio the rights to promote, market and sell all existing as well as future products including the Company’s revolutionary TruePrime™ products for primer-free whole genome amplification (WGA) as well as SunScript™ thermostable reverse transcriptase kits for the translation of RNA into DNA to researchers in molecular biology, oncology and clinical diagnostics in China.
As a leading solution provider, Nanodigmbio is offering a broad portfolio of quality research reagents as well as high-tech instruments in the wide fields of molecular biology, protein research, cell biology and diagnostics to customers all over China.
“We are very pleased about this distribution agreement for our proprietary product portfolio with Nanodigmbio, a leading distributor in China. With its wide customer network focused on molecular biology and diagnostics, Nanodigmbio is best positioned to leverage the benefits of our existing as well as future products to customers in genomics research especially in the fast growing field of NGS in China,” Pilar de la Huerta, CEO and CFO of SYGNIS commented. “China is a key market for us and together with Nanodigmbio we are persuing an aggressive strategy to enter this market. In parallel we are negotiating with key sequencing companies in China to provide them with our kits for their sequencing services.”
TruePrimeTM is the brand name of a revolutionary novel MDA technology and one of the key products in SYGNIS’ portfolio. TruePrime™ is based on the combination of SYGNIS proprietary DNA primase “TthPrimPol” and the extremely processive and high-fidelity Phi29 polymerase to amplify uniformly total genomic DNA for a multitude of applications including next generation sequencing and single cell analysis. The extraordinary strand displacement capacity of the Phi29 polymerase allows TthPrimPol to generate new primers on the displaced strands that are extended by Phi29 DNA pol, resulting in exponential isothermal DNA amplification without the need of any synthetic random primers.
SunScript™ RT is a reverse transcriptase that has been engineered for high thermostability, based on the well characterized human immunodeficiency virus RT (HIV-1 RT). The enzyme is active up to temperatures of 85°C. SunScript™ Reverse Transcriptase will be available in two versions: SunScriptTM RT RNaseH+ is optimized for the synthesis of complementary DNA (cDNA) as well as for use in reverse transcriptase (RT) PCR and quantitative PCR reactions for use e.g. in clinical diagnostics whereas SunScriptTM RT RNaseH- permits high yields of full length cDNA synthesis on long RNA molecules for the construction of cDNA libraries needed for example in next generation sequencing (NGS) applications, in gene expression profiling and molecular diagnostics.
For further information please contact:
Pilar de la Huerta
Phone: +34 91 192 36 50
MC Services AG
Phone: +49 89 210228 30